Trial reportJournal of cosmetic dermatology2026
Hydroquinone-Free, Tetrahexyldecyl Ascorbate Antioxidant Serum for Hyperpigmented and Photodamaged Skin to Achieve Skin Health.
Trial report in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
backgroundAscorbic acid (AA) has protective and corrective functions critical for counteracting extrinsic and intrinsic skin aging and hyperpigmentation, but it is highly unstable, making it challenging to formulate into skincare products. Tetrahexyldecyl (THD) Ascorbate, a lipid-soluble derivative of AA, has superior stability and skin-mimicking properties.
aimsTo investigate the efficacy and tolerability of a novel antioxidant serum containing 30% THD Ascorbate (THD-AA serum), a patent-pending blend of antioxidants and prebiotics, on photoaged and hyperpigmented skin with respect to long-term skin health.
methodsUsing preclinical models and a randomized, double-blind clinical trial, the antioxidant potential, antimelanogenesis, and antiaging properties of the THD-AA serum were evaluated.
resultsUsing an in vitro tissue model exposed to blue light, there was an 88% reduction in reactive oxygen species (ROS) formation after 30 min, 87% reduction after 60 min, and an 82% reduction after 120 min compared to the blue light-exposed control. Melanin production was reduced by 24% in vitro tissue co-culture. THD-AA serum improved the structural architecture of the skin, including the epidermis, dermal-epidermal junction, and dermis, and upregulated dermal collagen production 4-fold compared to a controlled moisturizer in an ex vivo model. In the clinical trial, existing damage and hyperpigmentation were visibly corrected on VISIA-CR and Antera 3D photographs, as well as in Clinical Grader results. There were no adverse events, and participants tolerated the serum well.
conclusionsTHD-AA serum has clinical and molecular efficacy in buffering ROS, reducing melanogenesis, and promoting antiaging, providing a safe alternative to hydroquinone products.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.